Researcher
Asif Hameed Khan
- Disciplines:Dermatology
Affiliations
- Department of Head and Skin (Department)
Member
From1 Oct 2018 → 25 Sep 2022 - Department of Otorhinolaryngology (Department)
Member
From18 May 2017 → 30 Sep 2018
Publications
1 - 10 of 90
- Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps(2022)
Authors: Joaquim Mullol, Claus Bachert, Nikhil Amin, Martin Desrosiers, Peter W Hellings, Joseph K Han, Roger Jankowski, Jan Vodicka, Nadia Daizadeh, Asif Hameed Khan, et al.
Pages: 1086 - 1095.e5 - Response to the correspondence : 'Non-optimal methodology questions indirect treatment comparison of dupilumab vs other biologics in severe asthma'(2022)
Authors: Eric D Bateman, Asif Hameed Khan, Yingxin Xu, Patricia Guyot, Paul Rowe, Heather Burnett, Jerome Msihid, David Weinreich, Ian Pavord
- Dupilumab improves health related quality of life : results from the phase 3 SINUS studies(2022)
Authors: Stella E Lee, Claire Hopkins, Joaquim Mullol, Jérôme Msihid, Isabelle Guillemin, Nikhil Amin, Leda P Mannent, Yongtao Li, Shahid Siddiqui, Chien Chia Chuang, et al.
Pages: 2211 - 2221 - Asthma Daytime Symptom Diary (ADSD) and Asthma Nighttime Symptom Diary (ANSD) : measurement properties of novel patient-reported symptom measures(2022)
Authors: Adam Gater, Linda Nelsen, Cheryl D Coon, Sonya Eremenco, Sean OU+2019Quinn, Asif Hameed Khan, Laurent Eckert, Hannah Staunton, Nicola Bonner, Rebecca Hall, et al.
Pages: 1249 - 1259 - Development of Sinonasal Outcome Test (SNOT-22) domains in chronic rhinosinusitis with nasal polyps(2022)
Authors: Asif Hameed Khan, Matthew Reaney, Isabelle Guillemin, Lauren Nelson, Shanshan Qin, Siddhesh Kamat, Leda Mannent, Nikhil Amin, Diane Whalley, Claire Hopkins
Pages: 933 - 941 - Dupilumab demonstrates rapid onset of response across three type 2 inflammatory diseases(2022)
Authors: G Walter Canonica, Arnaud Bourdin, Anju T Peters, Martin Desrosiers, Claus Bachert, Stephan Weidinger, Eric L Simpson, Nadia Daizadeh, Zhen Chen, Siddesh Kamat, et al.
Pages: 1515 - 1526 - Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps(2022)
Authors: Peter Hellings, Anju T Peters, Adam M Chaker, Enrico Heffler, Haixin Zhang, Amy Praestgaard, Scott Nash, Asif Hameed Khan, Shahid Siddiqui, Juby A Jacob-Nara, et al.
Pages: 958 - 962 - Dupilumab improves objective, subjective, and health-related quality of life outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP), regardless of BMIU+2265 30 kg/m2 or weightU+2265 90 kg : post-hoc analysis of the SINUS-24 and SINUS-52 studies(2022)Volume: 149
Authors: Seong Cho, Bruce Tan, Noam Cohen, Jody Tversky, Elina Toskala, Scott Nash, Haixing Zhang, Shahid Siddiqui, Asif Hameed Khan, Juby Jacob-Nara, et al.
Pages: AB143 - AB143 - Chronic rhinosinusitis : natural history, impact on health-related quality of life, and patient perspectives(2022)
Authors: Asif Hameed Khan
- Dupilumab achieves durable reduction in severity of symptoms rated most important by patients with chronic rhinosinusitis with nasal polyps(2022)Volume: 149
Authors: Claire Hopkins, Stella Lee, Wytske Fokkens, Eugene Chang, Jérôme Msihid, Asif Hameed Khan, Urvi Mujumdar, Siddhesh Kamat, Scott Nash, Shahid Siddiqui, et al.
Pages: AB142 - AB142